Tag archive for ‘neuromyelitis optica spectrum disorder’
MSCP wraps up $330m sale of majority stake in Hojeij Branded Foods to Lagardere
By pharmanewsdaily On Monday, February 1st, 2021
0 Comments

Horizon Therapeutics to acquire Viela Bio for $3bn to grow rare disease portfolio

Horizon Therapeutics, an Irish biopharma company, has agreed to acquire Viela Bio, a US-based biotech company, for $53 per share in cash or about $3.05 billion in a move to significantly expand its development pipeline More...

By pharmanewsdaily On Monday, December 14th, 2020
0 Comments

AstraZeneca to acquire US biopharma company Alexion Pharmaceuticals for $39bn

AstraZeneca acquisition of Alexion Pharmaceuticals : Pharma giant AstraZeneca has signed a $39 billion deal to acquire Alexion Pharmaceuticals, a US biopharma company engaged in developing therapies for rare disorders. As More...

MSCP wraps up $330m sale of majority stake in Hojeij Branded Foods to Lagardere
By pharmanewsdaily On Friday, June 12th, 2020
0 Comments

US biotech company Viela Bio bags Uplizna FDA approval for NMOSD

Uplizna FDA approval : US biotech company Viela Bio has secured approval from the US Food and Drug Administration (FDA) for Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of neuromyelitis More...